Virios Therapeutics, Inc. (VIRI) Q3 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning ladies and gentlemen, and thank you for your patience. This morning's conference call will begin soon. Please remain connected at this time. And once again, thank you for your patience. This morning's conference call will begin shortly. Thank you. Thank you. © transcript Emily Beynon Good day and welcome to the Vireos Therapeutics, Inc. Q3 earnings update. At this time, all participants have been placed on a listen-only mode. The floor will be open for questions and comments after the company presentation. It is now my pleasure to turn to proceedings over to Angela Walsh, SVP Finance and Treasurer, Vireos Therapeutics, Inc. Angela, the floor is yours. Thank you. Good morning, everyone, and thank you for joining us on today's conference call. We are pleased to be with you today to discuss Vireo Therapeutics' third quarter financial results, as well as to provide a summary of our ongoing analysis of the results from our recently completed Phase IIb Fibromyalgia Trial, also known as the FORTRESS Study. Please note that our financial results press release is now available on our website. We'll start today's call with our CEO, Greg Duncan, providing you with a brief update on our corporate progress during the past quarter. Then he will turn the call over to our Chief Medical Officer, Dr. Mike Genro, who will provide an update on our Fortress Study analysis. And then I will return to review our third quarter financial results. In addition, Ralph Goswald, our Senior Vice President of Operations, is with us for the question and answer portion of the call. Before we begin, I'd like to remind everyone that statements made during this conference call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, ...